Abstract
Ribonucleotide reductase inhibitors enhance the anti-HIV-1 activities of a variety of nucleoside analogs, including those that act as chain terminators and those that increase the HIV-1 mutation rate. However the use of these ribonucleotide reductase inhibitors is limited by their associated toxicities. The hydroxylated phytostilbene resveratrol has activity in a host of systems including inhibition of ribonucleotide reductase and has minimal toxicity. Here we synthesized derivatives of resveratrol and examined them for anti-HIV-1 activity and their ability to enhance the antiviral activity of decitabine, a nucleoside analog that decreases viral replication by increasing the HIV-1 mutation rate. The data demonstrates that six of the derivatives have anti-HIV-1 activity greater than resveratrol. However, only resveratrol acted in synergy with decitabine to inhibit HIV-1 infectivity. These results reveal novel resveratrol derivatives with anti-HIV-1 activity that may have mechanisms of action that differ from the drugs currently used to treat HIV-1.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 6642-6646 |
| Number of pages | 5 |
| Journal | Bioorganic and Medicinal Chemistry Letters |
| Volume | 22 |
| Issue number | 21 |
| DOIs | |
| State | Published - Nov 1 2012 |
Bibliographical note
Funding Information:This research was supported by a University of Minnesota Academic Health Center Translational Research Grant as well as by NIH Grant GM56615. C.L.C. was supported in part from NIH Grant T32 CA09138 (Cancer Biology Training Grant); M.A.B. was supported in part from NIH Grant T32 GM008700 (Chemistry-Biology Interface Training Grant).
Keywords
- Antiviral
- Decitabine
- HIV-1
- Mutagenesis
- Resveratrol
